374,929,920 H Shares of Biocytogen Pharmaceuticals Co., Ltd. are subject to a Lock-Up Agreement Ending on 31-AUG-2023.

Biocytogen Pharmaceuticals Beijing Co Ltd is a company mainly engaged in drug development business and preclinical research. The Company operates its business through five segments. The Gene-Editing services segment provides the customized gene-editing services based on animals as well as cells. The Pre-clinical Pharmacology and Efficacy Evaluation segment provides preclinical pharmacology services for the evaluation of drug efficacy and toxicity. The Animal Models Selling segment breeds and sells the animal models for the external and internal use. The Antibody Development segment utilises its antibody discovery platforms to identify antibodies which have the potential to become drug candidates. The Innovative Drugs Development segment is engaged in research and development of innovative drugs with a focus on oncology and autoimmune disease therapeutics. The Company also conducts its business through the Other segment.